Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non

Wu T.-H.Hsiue E.H.-C.JIH-HSIANG LEECHIA-CHI LINWEI-YU LIAOCHAO-CHI HOJIN-YUAN SHIHCHONG-JEN YUCHIH-HSIN YANG2022-09-152022-09-1520181525-7304https://www.scopus.com/inward/record.uri?eid=2-s2.0-85042180482&doi=10.1016%2fj.cllc.2018.01.005&partnerID=40&md5=ff989aaa989c27f3621d08892a21f68dhttps://scholars.lib.ntu.edu.tw/handle/123456789/620267[SDGs]SDG3Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non–Small-cell Lung Cancer Patientsjournal article10.1016/j.cllc.2018.01.005294773652-s2.0-85042180482